J. A. French Et Al. , "Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study," LANCET , vol.388, no.10056, pp.2153-2163, 2016
French, J. A. Et Al. 2016. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. LANCET , vol.388, no.10056 , 2153-2163.
French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nobbout, R., ... Curatolo, P.(2016). Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. LANCET , vol.388, no.10056, 2153-2163.
French, Jacqueline Et Al. "Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study," LANCET , vol.388, no.10056, 2153-2163, 2016
French, Jacqueline A. Et Al. "Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study." LANCET , vol.388, no.10056, pp.2153-2163, 2016
French, J. A. Et Al. (2016) . "Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study." LANCET , vol.388, no.10056, pp.2153-2163.
@article{article, author={Jacqueline A. French Et Al. }, title={Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study}, journal={LANCET}, year=2016, pages={2153-2163} }